307 related articles for article (PubMed ID: 37253487)
21. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
Syversen SW; Jyssum I; Tveter AT; Tran TT; Sexton J; Provan SA; Mjaaland S; Warren DJ; Kvien TK; Grødeland G; Nissen-Meyer LSH; Ricanek P; Chopra A; Andersson AM; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Lund-Johansen F; Jørgensen KK; Goll GL
Arthritis Rheumatol; 2022 Aug; 74(8):1321-1332. PubMed ID: 35507355
[TBL] [Abstract][Full Text] [Related]
22. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T
Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214
[TBL] [Abstract][Full Text] [Related]
23. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
Picchianti-Diamanti A; Aiello A; Laganà B; Agrati C; Castilletti C; Meschi S; Farroni C; Lapa D; Najafi Fard S; Cuzzi G; Cimini E; Grassi G; Vanini V; Di Rosa R; Salemi S; Nalli G; Salmi A; Repele F; Altera AMG; Maffongelli G; Palazzolo C; Vita S; Leone S; Puro V; Capobianchi MR; Ippolito G; Nicastri E; Goletti D
Front Immunol; 2021; 12():740249. PubMed ID: 34594343
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Borobia AM; Carcas AJ; Pérez-Olmeda M; Castaño L; Bertran MJ; García-Pérez J; Campins M; Portolés A; González-Pérez M; García Morales MT; Arana-Arri E; Aldea M; Díez-Fuertes F; Fuentes I; Ascaso A; Lora D; Imaz-Ayo N; Barón-Mira LE; Agustí A; Pérez-Ingidua C; Gómez de la Cámara A; Arribas JR; Ochando J; Alcamí J; Belda-Iniesta C; Frías J;
Lancet; 2021 Jul; 398(10295):121-130. PubMed ID: 34181880
[TBL] [Abstract][Full Text] [Related]
25. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
Front Immunol; 2022; 13():846248. PubMed ID: 35432314
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y
Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569
[TBL] [Abstract][Full Text] [Related]
27. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
29. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
[TBL] [Abstract][Full Text] [Related]
31. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
Bjørlykke KH; Ørbo HS; Tveter AT; Jyssum I; Sexton J; Tran TT; Christensen IE; Kro GB; Kvien TK; Jahnsen J; Munthe LA; Chopra A; Warren DJ; Mjaaland S; Haavardsholm EA; Grødeland G; Provan SA; Vaage JT; Syversen SW; Goll GL; Jørgensen KK
Lancet Rheumatol; 2023 Jan; 5(1):e36-e46. PubMed ID: 36415604
[TBL] [Abstract][Full Text] [Related]
32. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
[TBL] [Abstract][Full Text] [Related]
33. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases.
Cheung MW; Dayam RM; Shapiro JR; Law JC; Chao GYC; Pereira D; Goetgebuer RL; Croitoru D; Stempak JM; Acheampong L; Rizwan S; Lee JD; Jacob L; Ganatra D; Law R; Rodriguez-Castellanos VE; Kern-Smith M; Delgado-Brand M; Mailhot G; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Watts TH; Gingras AC
J Immunol; 2023 Aug; 211(3):351-364. PubMed ID: 37326480
[TBL] [Abstract][Full Text] [Related]
34. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents.
Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC
J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
36. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
37. Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.
Keeshan A; Galipeau Y; Heiskanen A; Collins E; McCluskie PS; Arnold C; Saginur R; Booth R; Little J; McGuinty M; Buchan CA; Crawley A; Langlois MA; Cooper C
BMJ Open; 2023 Oct; 13(10):e077714. PubMed ID: 37907304
[TBL] [Abstract][Full Text] [Related]
38. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
40. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
